Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114477 · ClinicalTrials.gov registry record
NeuroStar TMS Therapy System: Utilization and Outcomes
A clinical trial of Major Depressive Disorder, sponsored by Neuronetics.
- Completed
- Registry status
- 307
- Enrollment target
- 20
- Study locations
NCT01114477: Completed study of Major Depressive Disorder, sponsored by Neuronetics.
NCT01114477 is a study of Major Depressive Disorder that has completed, run by Neuronetics. The registered enrollment target is 307 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01114477, a study of Major Depressive Disorder, has completed, sponsored by Neuronetics.
- COMPLETED
- Registry status
- 307 participants
- Enrollment target
- 20
- Study locations
Study Summary
The major objective of this observational study is to describe clinical outcomes of patients receiving treatment with the NeuroStar TMS Therapy system in routine clinical practice.
Primary Outcome
The primary outcome measure will reported as the change from baseline through 6 weeks for the total score on the PHQ-9.
Conditions Studied
Study Locations (20)
California
- Bay Psychiatric Associates - Berkeley
- TMS Center of Beverly Hills - Beverly Hills
- Clinical Training & Research Institute - Burlingame
- Sacramento TMS - El Dorado Hills
- Martha Koo, MD - Hermosa Beach
- Orange County TMS Center - Laguna Hills
- Depression Research Center and Clinic-Semel Institute for Neuroscience & Human Behavior at UCLA - Los Angeles
- Kevin Kinback, MD - Mission Viejo
- Todd Hutton, MD & Associates - Pasadena
- The Botkiss Center for TMS Therapy - San Diego
- Stanford Hospital and Clinics - Stanford
- Arjun Reyes, MD - Woodland Hills
Connecticut
- Hartford Hospital - Hartford
- Comprehensive Psychiatric Care - Norwich
Florida
- Health Sciences America, LLC - Boca Raton
- Curtis Cassidy, MD - Lakeland
Arizona
- Lee Ann Kelley, M.D., PC - Phoenix
Delaware
- Christiana Care Health Services - Wilmington
Georgia
- Brian Teliho, MD - Atlanta
Illinois
- Carl M. Wahlstrom, Jr. MD Limited - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-09 |
What the finished NCT01114477 record still lists
NCT01114477 is an observational study that tracks outcomes without assigning an intervention. The registered 307 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (18% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT01114477 names 20 study sites across 7 states, led by California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT01114477 about?
NCT01114477 is a clinical study titled "NeuroStar TMS Therapy System: Utilization and Outcomes". The major objective of this observational study is to describe clinical outcomes of patients receiving treatment with the NeuroStar TMS Therapy system in routine clinical practice.
What is the current status of trial NCT01114477?
This trial is currently completed. The enrollment target is 307 participants. The study started on 2010-03. Estimated completion is 2012-09.
What conditions does trial NCT01114477 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
Who is sponsoring clinical trial NCT01114477?
This trial is sponsored by Neuronetics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01114477 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01114477's enrollment target sits among peer trials
307 53rd of 282 higher than 230 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Taking Action for College Students
RECRUITING · NA
-
Neural Response to Inflammatory Challenge in Major Depressive Disorder
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05433142 · 307 participants · Phase 1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia